×
SANUWAVE Health is expected to report third-quarter 2026 results, with a conference call scheduled for November 11, 2026. Wall Street consensus calls for earnings of roughly $0.01 per share and revenue near $13.75 million, versus $0.46 in EPS and $11.45 million in revenue a year ago.
Rapid Micro Biosystems is expected to report its third quarter 2026 results on or around November 5, 2026. Analyst consensus points to third-quarter revenue near $10.1 million and a net loss of roughly $0.20 per share, above the company's guidance of at least $9.5 million in revenue.
Treace Medical Concepts reported third quarter 2026 revenue of $48.3 million , down 4% from $50.2 million a year earlier. Net loss narrowed to $12.6 million , or $0.19 per share, from a loss of $16.3 million, or $0.26 per share, in the prior-year quarter.
ATEC slid -4.1% during regular trading, falling from a $7.80 prior close to about $7.48. No new company-specific news today: the decline extends the selloff from the Oct 30 Q3 miss and FY2026 revenue-guidance cut to ~$862M, with this week's UBS and BMO downgrades keeping shares under pressure.
BBNX shares slipped -3.62% during Friday's regular session, falling from a prior close of $15.49 to $14.93. No verified news or fundamental catalyst found. The move is consistent with the stock's normal volatility, as it has averaged roughly a 4% daily swing over the past 60 sessions, making a -3.62% decline unremarkable.
OFIX slid -10.65% intraday during regular trading hours, from a prior close of $8.92 to about $7.97. No verified news or fundamental catalyst found. With Q3 results due Nov 9 before the open, the drop appears consistent with pre-earnings de-risking and sector-driven selling that broke the stock below its $8.50 52-week low.
GMED slid from a prior close of $81.44 to about $72.42, a drop of -11.08%, during Thursday's regular session after steep after-hours and premarket losses. The decline followed Q3 results reported after Wednesday's close: revenue of $763.7M missed the ~$792M consensus and management cut full-year 2026 revenue guidance to ~$3.09B from $3.18B–$3.22B, overshadowing an EPS beat.
AORT dropped sharply during Friday's regular session, falling from a prior close of $25.33 to about $20.15, a decline of -20.45%. The selloff followed Q3 results released after Thursday's close: revenue beat estimates, but adjusted EPS missed, gross margin slid to 61.4%, and the company posted a $7.9M GAAP net loss, negative free cash flow, and a new ~$10M 2027 PerClot revenue headwind.
IRTC fell -33.17% to $87.00 from a prior close of $130.19, with the drop unfolding in the November 6 regular session after an after-hours earnings decline. The selloff followed Q3 results reported after the November 5 close, headlined by news the company no longer plans to submit its Zio MTC mobile cardiac monitor to the FDA this year, pushing the filing to 2027.
PFSA slid from a previous close of $0.5698 to $0.52, a decline of -8.74%, during regular trading, extending a premarket drop that set a new 52-week low. No verified news or fundamental catalyst found. The move is consistent with persistent selling pressure and extremely thin liquidity in this micro-cap, which routinely swings by double-digit percentages.
CVRx shares dropped from a $1.47 prior close to about $0.84, a -42.86% decline, during regular trading hours on Nov. 6. The catalyst: Q3 results (after the Nov. 5 close) missed on earnings and revenue, management cut full-year guidance for a second straight quarter to $56–57M, and a key Medicare Advantage payer's approval rate collapsed to ~12%, triggering downgrades from William Blair, Canaccord, and Lake Street.
Baird Medical (BDMD) dropped to about $0.0914 from a previous close of $0.1575 in early regular-session trading, a decline of roughly -42%. The slide extends a months-long collapse in this micro-cap after a Nasdaq minimum-bid-price deficiency notice (delisting risk) disclosed Nov. 4, and reverses most of Thursday's +47% spike on Alpmed's IRE regulatory filings; the company said it is unaware of any material reason for the decline.
RCEL jumped from Wednesday's $15.68 close to roughly $16.89, a gain of +7.72%, during regular market hours. The move extends an after-hours rally sparked by Q3 results released Wednesday evening that beat estimates and included a raised full-year revenue outlook and removal of the going-concern warning.
TMDX surged during regular trading hours, climbing from $68.98 to $83.50, a gain of +21.05%. The move followed a strong Q3 2026 earnings beat: non-GAAP EPS of $0.51 crushed the ~$0.30 consensus, revenue of $203M topped estimates, and full-year revenue guidance was raised to $764M–$774M.
PROF dropped -3.49% during regular trading, sliding from a prior close of $6.88 to $6.64. The decline extends the market's reaction to Q3 2026 results released after Wednesday's close: record revenue of $9.8 million (+86% YoY) but an EPS miss of -$0.21 versus -$0.19 consensus and cash shrinking to $33.3 million.
Enovis (ENOV) fell -5.94% to $26.92 from a prior close of $28.62 during regular trading hours. The drop is profit-taking after shares climbed roughly +38% over the prior two sessions on a Q3 beat (adjusted EPS of $0.88 vs. $0.77 consensus), raised full-year guidance, and a new $200 million buyback announced Nov. 5.
TNDM fell during regular trading on November 6, sliding from its previous close of $17.99 to $16.74, a decline of -6.95%. The drop reversed an after-hours pop: Tandem beat Q3 estimates (loss of -$0.10 vs -$0.25 expected; revenue $283.7M vs ~$264M), but soft forward guidance — implied Q4 revenue about -6.8% below consensus and 2027 growth of mid-to-high single digits versus ~12% consensus — outweighed the beat.
GMED slid -8.20% in regular trading, falling from a prior close of $81.44 to $74.76. The drop extends a post-earnings selloff: Q3 2026 results reported after the November 5 close missed revenue estimates, and management issued its first full-year revenue guidance cut to $3.09 billion.
Inogen (INGN) fell from a previous close of $6.77 to $5.65, a -16.54% drop, during regular market hours Thursday as the post-earnings selloff carried into the session. The catalyst was Q3 results released after the Nov. 5 close: revenue of $77.2M badly missed the roughly $92M consensus and full-year guidance was slashed.
IRTC dropped -26.93% to $95.13 from its prior close of $130.19, with the slide extending through the November 6 regular session after starting in after-hours trading. The move followed Q3 results reported after the November 5 close: revenue of $221.6M missed estimates, GAAP EPS swung to -$0.90 on litigation settlement charges, and full-year revenue guidance came in below consensus amid slowing Zio AT demand and a delayed Zio MCT FDA submission.
Previous
13 of 31
Next